These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 26146845)

  • 1. Likelihood of use and perception towards biosimilars in rheumatoid arthritis: a global survey of rheumatologists.
    Narayanan S; Nag S
    Clin Exp Rheumatol; 2016; 34(1 Suppl 95):S9-11. PubMed ID: 26146845
    [No Abstract]   [Full Text] [Related]  

  • 2. Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists.
    van Overbeeke E; De Beleyr B; de Hoon J; Westhovens R; Huys I
    BioDrugs; 2017 Oct; 31(5):447-459. PubMed ID: 28929342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilars in rheumatology: pharmacological and pharmacoeconomic issues.
    Lapadula G; Ferraccioli GF
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S102-6. PubMed ID: 23078880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis.
    Yoo DH
    Expert Rev Clin Immunol; 2014 Aug; 10(8):981-3. PubMed ID: 24961712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilars and drug development in allergic and immunologic diseases.
    Bonini S; Bonini M
    J Allergy Clin Immunol; 2017 May; 139(5):1461-1464. PubMed ID: 28359671
    [No Abstract]   [Full Text] [Related]  

  • 6. Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK.
    Aladul MI; Fitzpatrick RW; Chapman SR
    BioDrugs; 2017 Dec; 31(6):533-544. PubMed ID: 29127626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biosimilars for the management of rheumatoid arthritis: economic considerations.
    Gulácsi L; Brodszky V; Baji P; Kim H; Kim SY; Cho YY; Péntek M
    Expert Rev Clin Immunol; 2015; 11 Suppl 1():S43-52. PubMed ID: 26395836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologicals and how they revolutionized rheumatology.
    Grisar J
    Wien Med Wochenschr; 2015 Jan; 165(1-2):1-2. PubMed ID: 25676698
    [No Abstract]   [Full Text] [Related]  

  • 9. Biosimilars versus biologics for inflammatory conditions.
    Perry D; Ton J; Kolber MR
    Can Fam Physician; 2019 Sep; 65(9):636. PubMed ID: 31515313
    [No Abstract]   [Full Text] [Related]  

  • 10. The confidence of rheumatologists about switching to biosimilars for their patients.
    Goll GL; Haavardsholm EA; Kvien TK
    Joint Bone Spine; 2018 Oct; 85(5):507-509. PubMed ID: 29631065
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of moderate rheumatoid arthritis with different strategies in a health resource-limited setting: a cost-effectiveness analysis in the era of biosimilars.
    Wu B; Song Y; Leng L; Bucala R; Lu LJ
    Clin Exp Rheumatol; 2015; 33(1):20-6. PubMed ID: 25438197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis.
    Aladul MI; Fitzpatrick RW; Chapman SR
    Res Social Adm Pharm; 2019 Mar; 15(3):310-317. PubMed ID: 29807834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimation of cost savings between 2011 and 2014 attributed to infliximab biosimilar in the South Korean healthcare market: real-world evidence using a nationwide database.
    Kim J; Ha D; Song I; Park H; Lee SW; Lee EK; Shin JY
    Int J Rheum Dis; 2018 Jun; 21(6):1227-1236. PubMed ID: 29667324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilars: Reimbursement Issues in Your Oncology Practice.
    Conti RM
    J Oncol Pract; 2017 Sep; 13(9_suppl):12s-14s. PubMed ID: 28898590
    [No Abstract]   [Full Text] [Related]  

  • 15. Of patents and patent disputes - The TNFα patent files. Part 2: Enbrel, Remicade, Cimzia and Simponi.
    Storz U
    Hum Antibodies; 2018 Feb; 26(2):49-61. PubMed ID: 29439320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wide difference in biologics usage and expenditure for the treatment of patients with rheumatoid arthritis in each prefecture in Japan analyzed using "National Database of Health Insurance Claims and Specific Health Checkups of Japan".
    Kamata Y; Minota S
    Rheumatol Int; 2018 Apr; 38(4):663-668. PubMed ID: 29204683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacoeconomics of Biosimilars: What Is There to Gain from Them?
    Araújo FC; Gonçalves J; Fonseca JE
    Curr Rheumatol Rep; 2016 Aug; 18(8):50. PubMed ID: 27402107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
    Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
    Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Of patents and patent disputes: The TNFα patent files. Part 1: Humira.
    Storz U
    Hum Antibodies; 2017; 25(1-2):1-16. PubMed ID: 27792008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilars for Rheumatoid Arthritis: Don't Count Them Out Quite Yet.
    Rychlick N
    Manag Care; 2018 Jan; 27(1):29. PubMed ID: 29369768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.